ADMA — ADMA Biologics, Inc.

ADMA Biologics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $134.2 million, a 10% increase quarter-over-quarter and 12% year-over-year.
• GAAP Net Income: $36.4 million, up 6% from Q2 and 1% from the prior year.
• Adjusted EBITDA: $58.7 million, reflecting a 16% quarter-over-quarter increase and a 29% year-over-year growth.
• Gross Margin: Expanded to approximately 56.3%, up from 49.8% year-over-year; product-level gross margins reached 63.7% excluding plasma sales.
• Cash Position: Approximately $23 million in share repurchases during the quarter, with a strong balance sheet and an undrawn $225 million revolving credit facility.

2. Strategic Updates and Business Highlights:

• ASCENIV Performance: Record utilization driven by strong prescriber adoption and sustained patient demand. Positive payer negotiations for 2026 are expected to improve access and reimbursement.
• Clinical Data: A study showed a more than 50% reduction in infection rates for patients switching from standard immunoglobulin therapy to ASCENIV, with plans for peer-reviewed publication and presentations at upcoming conferences.
• Production Enhancements: FDA approval of yield-enhanced production batches is anticipated to improve gross margins starting Q4 2025 and throughout 2026.
• Pipeline Development: The SG-001 program is progressing, with a CNPV voucher application submitted to the FDA to expedite regulatory review.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Increased to $510 million from prior guidance of over $500 million. Adjusted net income expected to be $158 million, with adjusted EBITDA guidance maintained at $235 million.
• 2026 Revenue Guidance: Projected to be at least $630 million, up from $625 million, with adjusted net income raised to over $255 million and adjusted EBITDA expected to exceed $355 million.
• Long-Term Outlook: Revenue for fiscal year 2029 is expected to exceed $1.1 billion, with potential contributions from SG-001 excluded from this forecast.

4. Bad News, Challenges, or Points of Concern:

• Competitive Dynamics: Temporary competitive pressures in the standard IVIG market impacted BIVIGAM, contributing to a higher effective tax rate affecting net income.
• Market Conditions: While ASCENIV demand is strong, there are ongoing challenges in the standard IVIG market, which could influence overall performance.
• Payer Negotiations: While progress is being made, there is uncertainty regarding potential discounts or rebates that may be required to secure improved access.

5. Notable Q&A Insights:

• Clinical Data Impact: The significant reduction in infections with ASCENIV is expected to enhance prescriber confidence and payer negotiations.
• Growth Projections: The company anticipates strong double-digit growth in ASCENIV utilization, supported by improved payer access and ongoing medical education efforts.
• Plasma Supply: ADMA's partnerships with third-party suppliers are yielding positive results, with expectations for increased plasma collection in 2026.
• Physician Engagement: The number of prescribing physicians is increasing, with a focus on expanding the clinician base to drive future growth.

Overall, ADMA Biologics reported strong financial results and strategic advancements, particularly with ASCENIV, while navigating challenges in the competitive landscape and payer negotiations. The company remains optimistic about future growth and operational improvements.